Literature DB >> 33355023

Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis.

Fahimeh Ramezani Tehrani1, Samira Behboudi-Gandevani2, Razieh Bidhendi Yarandi1, Marzieh Saei Ghare Naz1, Enrico Carmina3.   

Abstract

OBJECTIVE: The aim of this meta-analysis was to evaluate the prevalence of acne among women with PCOS worldwide, and in subgroups of patients with different age, geographical-region, and PCOS definition-criteria, compared to healthy non-PCOS counterparts.
METHODS: A comprehensive literature search was performed in PubMed (including Medline), Web of Science, and Scopus databases for retrieving articles in English investigating the prevalence of PCOS. 'Meta-prop' method was applied to estimate pooled prevalence of acne in both groups. Meta-regression was conducted to find the association between acne in women with and without PCOS.
RESULTS: We used 60 studies, included data of 240,213 women with PCOS and 1,902,022 healthy-controls for the meta-analysis. The overall pooled prevalence of acne among women with and without PCOS, was 43% (95% CI: 41-45%) and 21% (95% CI: 19-22%), respectively, which was 1.6-fold significantly higher than among healthy-controls. The pooled prevalence of acne in adults, and in adolescents PCOS patients were 42 and 59%, respectively, which were significantly higher than non-PCOS counterparts. The pooled estimated prevalence of acne in adult PCOS women was 76% using the NIH definition and 36% by Rotterdam-criteria; both were significantly higher than non-PCOS counterparts, respectively. In subgroups of adults, who used Rotterdam-definition, the highest prevalence of acne in PCOS patients was reported in East Asia and was 3.5-fold higher than non-PCOS counterparts.
CONCLUSIONS: Despite the presence of heterogeneity and publication bias among available literature, it may be concluded that acne is one of the common dermatological manifestations in PCOS. In addition, results highlight geographical differences among PCOS patients.

Entities:  

Keywords:  Acne; meta-analysis; polycystic ovary syndrome; prevalence

Mesh:

Year:  2020        PMID: 33355023     DOI: 10.1080/09513590.2020.1859474

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

Review 1.  A Review on CYP11A1, CYP17A1, and CYP19A1 Polymorphism Studies: Candidate Susceptibility Genes for Polycystic Ovary Syndrome (PCOS) and Infertility.

Authors:  Roozbeh Heidarzadehpilehrood; Maryam Pirhoushiaran; Rasoul Abdollahzadeh; Malina Binti Osman; Maryam Sakinah; Norshariza Nordin; Habibah Abdul Hamid
Journal:  Genes (Basel)       Date:  2022-02-05       Impact factor: 4.096

2.  What can be done to improve polycystic ovary syndrome (PCOS) healthcare? Insights from semi-structured interviews with women in Canada.

Authors:  Miya Ismayilova; Sanni Yaya
Journal:  BMC Womens Health       Date:  2022-05-10       Impact factor: 2.742

Review 3.  Dermatology: how to manage acne vulgaris.

Authors:  Alexander Kc Leung; Benjamin Barankin; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2021-10-11

4.  Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

Authors:  Enrico Carmina; Brigitte Dreno; W Anne Lucky; W George Agak; Anuja Dokras; Jin Ju Kim; Rogerio A Lobo; Fahimeh Ramezani Tehrani; Daniel Dumesic
Journal:  J Endocr Soc       Date:  2022-02-06

5.  The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.

Authors:  Mahbanoo Farhadi-Azar; Samira Behboudi-Gandevani; Maryam Rahmati; Fatemeh Mahboobifard; Ensi Khalili Pouya; Fahimeh Ramezani Tehrani; Fereidoun Azizi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

Review 6.  Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review.

Authors:  Alexia S Peña; Ethel Codner; Selma Witchel
Journal:  Diagnostics (Basel)       Date:  2022-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.